advanced search

Welcome: Guest

log in

Viropharma Incorporated: Strategic Corporate Assessment

Strategy, SWOT Analysis and 5-year Financial Insights with In-depth Company Profile

Publication Date August 2008
Publisher Datamonitor
Product Type Report
Pages 48
ISBN Number not applicable
Product Code DAT08224
Buy this product or for assistance call +44 20 7060 7474

Summary

Introduction

ViroPharma focuses on the development and commercialization of medicines to address diseases associated with hospital settings, transplant medicine and gastroenterology.

Scope

  • Contains corporate strategy, value chain presence and SWOT Analysis
  • Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
  • Includes information on suppliers/ partners, shareholding structure and key employees with biographies

Highlights

The company's total revenues increased at a CAGR of 134% during 2002-2006, from $6 million to $167 million. The company's biggest contributor to revenue growth during 2002-2006 was product sales of Vancocin.

The company's biggest contributor to sales growth out to 2010 will continue to be Vancocin.However, revenues from Vancocin are expected to increase only at a CAGR of 1%, from $167 million in 2006 to $175 million in 2010. This could be attributable to generic competition for Vancocin, whose patent expired in 1996.

Reasons to Purchase

  • Access all the important information and analysis on the company in a single report
  • Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain
  • Gain access to company's adjusted five year financial data along with key ratios and market capitalization

Content

  • Overview
  • Catalyst
  • Summary
  • Company Structure
  • Company Overview and Key Facts
  • Business Description
  • History
  • Company Financials
  • Stock Market Performance
  • P&L
  • Balance Sheet
  • Cash Flow
  • Products & Services
  • Marketed Products
  • Pipeline Products
  • Historical Product Sales
  • AC Forecast Product Sales
  • Competitors and Strategic Business Relationships
  • Key Competitors
  • Key Suppliers
  • Key Clients
  • Shareholding Structure
  • Strategy
  • Company View
  • Corporate Strategy
  • SWOT Analysis
  • Overview
  • Strengths
  • Weaknesses
  • Opportunities
  • Threats
  • Value Chain Analysis
  • Overview
  • Discovery and Product Development
  • Sales
  • Scorecard
  • Overview
  • Scorecard Analysis
  • Key Employees
  • List of Key Employees
  • Key Employee Biographies
  • Financial and Operational Overview
  • Financial and Operational Overview
  • APPENDIX
  • Ask the analyst
  • Datamonitor consulting
  • Disclaimer
  • TABLE OF FIGURES
    • Figure1: ViroPharma- Operating Revenue/Cost Analysis, 200307 ($ Mn)
    • Figure2: ViroPharma- Key Strategic Products Revenues, 200711 ($ Mn)
  • TABLE OF TABLES
    • Table 1: ViroPharma- Key Facts
    • Table 2: ViroPharma- Year-End Share Price and Market Capitalization, 200307 ($)
    • Table 3: ViroPharma- Key Events Impacting Share Price Performance, 200307
    • Table 4: ViroPharma- Operating Revenue/Cost Analysis, 200307 ($ Mn)
    • Table 5: ViroPharma- Operating Cost Ratio Analysis, 200307 (% of total revenues)
    • Table 6: ViroPharma- Balance Sheet, 200307 ($ Mn)
    • Table 7: ViroPharma- Cash Flow, 200307 ($ Mn)
    • Table 8: ViroPharma- Marketed Products
    • Table 9: ViroPharma- In-house Pipeline Products
    • Table 10: ViroPharma- Historical Product Sales, 200307 ($ Mn)
    • Table 11: ViroPharma- Forecast Sales, 200711 ($ Mn)
    • Table 12: ViroPharma- Key Competitors
    • Table 13: ViroPharma- Key Suppliers
    • Table 14: ViroPharma- Key Clients
    • Table 15: ViroPharma- Key Shareholders
    • Table 16: ViroPharma- SWOT Analysis Summary
    • Table 17: ViroPharma Value Chain Analysis
    • Table 18: ViroPharma- Scorecard
    • Table 19: ViroPharma- Key Employees
    • Table 20: ViroPharma - Financial and Operational Overview
Delivery Details

PDF:Delivered by email usually within 4 to 8 UK business hours.

PRINT/CD-ROM:Despatched within 1 to 2 working days.

Industry Events

Oncology Market & Patient Access

14 Dec 09 to 16 Dec 09
Prague, Czech Republic
view summary >>

Orphan & Ultra Orphan Drugs

13 Jan 10 to 14 Jan 10
Brussels, Belgium
view summary >>